Project Grant R01NS138402
Award Date
7/17/24
Completion Date
6/30/28
Dollars Obligated
$682K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This Project Grant award, valued at $635,430.00 and effective from July 22, 2024 to June 30, 2029, is funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The project aims to advance the understanding of how regulatory genetic variation contributes to the risk and progression of Parkinson's disease (PD). Key objectives include defining the chromatin and...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), provides $858,471 to support research focused on understanding the role of N-terminal acetylation in alpha-synuclein stability, function, and therapeutic targeting for synucleinopathies like Parkinson's disease (PD) and Alzheimer's disease-related dementias (ADRD). The key objectives of this 5-year grant (award date: September 13, 2024) are...
This $655,329 federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the role of the GPNMB gene in the pathogenesis of Parkinson's disease, Lewy body dementia, and related synucleinopathies. The research team at Albert Einstein College of Medicine will employ CRISPR/Cas9 genome editing in human...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $616,200.00 to support research into the influence of neuromelanin on single dopaminergic neurons in Parkinson's disease. The primary objective is to leverage expertise across three established labs to explore how progressive neuromelanin accumulation in dopamine...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, provides $245,847.00 to Duke University to investigate the role of the Integrated Stress Response (ISR) pathway in dopamine neurons and its implications for Parkinson's disease. The project, titled "The ISR Pathway in Dopamine Neurons: Perpetrator or Protector in Parkinson's Disease," aims to examine ISR states in dopamine neuron subclasses in...
This $684,451 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports comprehensive research to advance understanding and treatment of Parkinson's disease (PD). The project aims to: Identify PD progression subtypes through integrative modeling of longitudinal clinical, transcriptomic, and neuroimaging data from the Parkinson's Progression...
The federal Project Grant award of $173,140 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to elucidate the role of neural activity in the degeneration of midbrain dopamine neurons in Parkinson's disease. The project aims to utilize novel mouse models to chronically manipulate the activity and dopamine metabolism within dopamine neurons,...
This $406,260 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research to define the molecular mechanisms that contribute to neurodegeneration in Parkinson's disease (PD) and related dementias. The research aims to establish a role for alpha-synuclein-mediated membrane permeabilization in the spread of alpha-synuclein...
This $2,192,716 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to understand the role of serine-129 phosphorylation in the aggregation and spreading of α-synuclein pathology associated with Parkinson's disease, dementia with Lewy bodies, and related synucleinopathies. The project leverages novel serine-129 phospho-deficient and...
This $163,750 federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to identify innovative drug candidates for treating Parkinson's disease (PD) and dementia with Lewy bodies (DLB) related to mutations in the GBA1 gene. The project aims to perform high-throughput screening of 11,280 small molecule compounds to boost...